Boehringer Ingelheim

Rediff.com » News » Boehringer Ingelheim

News for Boehringer Ingelheim

Business

Price relief for diabetes patients as drugs go off patent

At least two key drugs in the gliptin category have already gone off patent and cheaper variants are crowding the market. Also, several patent expiries are round the corner for the newest category......

Prices of key diabetes, cancer drugs may drop by 25%

A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments. The next......

Earning woes drag markets lower; TCS, HUL lead fall

Markets closed lower for the third straight day with IT giant TCS leading the fall after its Q2 results missed street expectations while lower dollar revenue guidance from Infosys on Monday also......

US FDA tightens regulatory noose on Indian drug firms

Import alert on Ranbaxy’s Mohali unit; Strides’ injectible arm gets warning letter Indian drug makers have again come under the scrutiny of the US Food and Drug Administration (US FDA),......

Wockhardt launches prostate drug in US market

Pharma major Wockhardt on Wednesday said it has launched Tamsulosin capsules, indicated for problem of prostate enlargement, in the US market on the day one of the expiry of patent covering the......

Rediff News

Boehringer Ingelheim

News for Boehringer Ingelheim

Price relief for diabetes patients as drugs go off patent

Prices of key diabetes, cancer drugs may drop by 25%

Earning woes drag markets lower; TCS, HUL lead fall

US FDA tightens regulatory noose on Indian drug firms

Wockhardt launches prostate drug in US market

Top Coverage News

World Test Championship 2023

Manipur's Tragedy

IPL 2023

Sri Lanka's Tour of India 2023

GUJARAT, HIMACHAL GO TO POLLS